Valuation : Niagen Bioscience, Inc.

Market Cap 248M 214M 201M 183M 345M 23.55B 347M 2.38B 927M 11.98B 932M 912M 39.73B P/E 2026 *
23.4x
P/E 2027 * 20.3x
Enterprise Value 248M 214M 201M 183M 345M 23.55B 347M 2.38B 927M 11.98B 932M 912M 39.73B EV / Sales 2026 *
1.86x
EV / Sales 2027 * 1.6x
Free-Float
70.54%
Yield 2026 *
-
Yield 2027 * -
08-06 Niagen Bioscience, Inc. Launches Tru Niagen On Walmart.com, Expanding Access And Diversifying Its E-Commerce Marketplace Presence CI
08-04 Niagen Bioscience, Inc., Q2 2026 Earnings Call, Aug 04, 2026
08-04 Tranche Update on Niagen Bioscience, Inc.'s Equity Buyback Plan announced on November 6, 2025. CI
08-04 Niagen Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Niagen Bioscience, Evotec to Advance Preclinical Development of NB4168 MT
07-28 Niagen Bioscience Announces Newly Published Analysis Demonstrating Niagen Supplementation Improves Muscle-Specific Marker of Biological Aging CI
07-16 Niagen Bioscience, Inc. Announces Appointment of Abhijit Kale as Senior Director of Global External Research, Effective July 20, 2026 CI
07-15 Niagen Bioscience, Inc. - Special Call
07-13 Niagen Bioscience Receives U.S. Fda Rare Pediatric Disease Designation and European Medicines Agency Orphan Medicinal Product Designation for Nb4168 for Treatment of Ataxia Telangiectasia CI
07-13 Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia MT
07-08 Niagen Bioscience Launches Pharmaceutical Program And Advances NB4168 As First Drug Candidate For Accelerated Aging And Rare Genetic Diseases CI
07-08 Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases MT
05-21 NARB recommends Niagen modify/discontinue certain Tru Niagen NAD+ dietary supplement claims RE
1 day-5.43%
1 week-2.40%
Current month-5.43%
1 month-7.58%
3 months-23.75%
6 months-40.49%
Current year-54.39%
1 week 2.44
Extreme 2.44
2.58
1 month 2.16
Extreme 2.16
2.82
Current year 2.16
Extreme 2.16
5.6
1 year 2.16
Extreme 2.16
8.4
3 years 1.18
Extreme 1.18
12.4
5 years 1.17
Extreme 1.17
12.4
10 years 1.17
Extreme 1.17
19
Manager TitleAgeSince
Chief Executive Officer 66 2018-05-31
Director of Finance/CFO 35 2024-10-20
Chief Tech/Sci/R&D Officer - 2020-06-30
Director TitleAgeSince
Chairman 57 2018-06-21
Director/Board Member 66 2015-07-08
Director/Board Member 65 2017-03-26
Change 5-day change 1-year change 3-year change Capi.($)
-5.43%-2.40% - - 248M
+0.21%-2.69%+1.19%+17.32% 49.81B
+2.09%-0.71%+452.73%+498.77% 44.06B
-1.09%-0.41%+35.40%+15.17% 42.99B
-0.26%-4.71%+17.19%+71.67% 40.88B
-0.48%-0.84%+16.25%+49.80% 33.11B
-1.81%-5.02%+22.65%+113.24% 16.58B
-1.06%+2.87% - - 17.27B
-1.35%-3.40%+10.13%+26.34% 14.63B
-2.05%-5.14%+72.89%+34.69% 13.76B
Average -1.28%-2.11%+78.55%+103.38% 30.34B
Weighted average by Cap. -0.51%-1.88%+94.97%+120.43%

Financials

2026 *2027 *
Net sales 133M 115M 108M 98.4M 185M 12.63B 186M 1.28B 497M 6.43B 500M 489M 21.31B 155M 134M 126M 115M 216M 14.74B 217M 1.49B 580M 7.5B 583M 570M 24.86B
Net income 10.88M 9.39M 8.83M 8.05M 15.13M 1.03B 15.21M 104M 40.64M 525M 40.87M 39.98M 1.74B 12.82M 11.06M 10.4M 9.48M 17.82M 1.22B 17.92M 123M 47.87M 619M 48.14M 47.1M 2.05B
Net Debt - -
Logo Niagen Bioscience, Inc.
Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities.
Employees
117
Date Price Change
26-09-01 €2.440 -5.43%
26-08-31 €2.580 +3.20%
26-08-28 €2.500 -3.10%
26-08-27 €2.580 +9.32%
26-08-26 €2.360 -5.60%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.130USD
Average target price
12.08USD
Spread / Average Target
+286.05%

Quarterly revenue - Rate of surprise